Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 1:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,342 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gastrointestinal System--Abnormalities Clear all
Completed No phase listed Observational

Viral Pathogenesis of Early Cystic Fibrosis Lung Disease

NCT01973192
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
2 Months to 4 Months
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Indianapolis, Indiana • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 29, 2026, 1:02 AM EDT
Completed No phase listed Observational

Splanchnic and Renal Tissue Oxygenation During Enteral Feedings in Neonates With Patent Ductus Arteriosus

NCT03551600
View directory record Official record
Conditions
Infant, Premature, Congenital Heart Disease, Patent Ductus Arteriosus, Necrotizing Enterocolitis
Interventions
Near-infrared spectroscopy (NIRS)
Procedure
Lead sponsor
University of Utah
Other
Eligibility
12 Days to 6 Months
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
3
States / cities
Murray, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 29, 2026, 1:02 AM EDT
Terminated Not applicable Interventional Results available

Airway Clearance for Pediatric and Adult Cystic Fibrosis Patients Using a Portable Intra-Pulmonary Percussion Device

NCT04743206
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Standard Airway Clearance device, Portable Internal Airway Percussion device
Device
Lead sponsor
University of Florida
Other
Eligibility
6 Years to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 29, 2026, 1:02 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency

NCT01371825
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency, Wolman Disease
Interventions
Sebelipase alfa (SBC-102)
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 24 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 29, 2026, 1:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Muscle Accrual and Function in Cystic Fibrosis-Impact of Glucose Intolerance

NCT02776098
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
12 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 29, 2026, 1:02 AM EDT
Completed Not applicable Interventional

Multimedia Intervention in Patients With Familial Adenomatous Polyposis (FAP)

NCT00525655
View directory record Official record
Conditions
Familial Adenomatous Polyposis, Colorectal Cancer
Interventions
Web-Based Multimedia Intervention, Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
13 Years to 24 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 29, 2026, 1:02 AM EDT
Recruiting Not applicable Interventional

Milk for Diabetes Prevention

NCT06513026
View directory record Official record
Conditions
Lactose Intolerance, Lactose Intolerant, Lactase Persistence, Pre-Diabetes, Diabetes Mellitus, Type 2
Interventions
Lactose-Containing Milk, Lactose-Free Milk
Dietary Supplement
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 29, 2026, 1:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

NCT03711058
View directory record Official record
Conditions
Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor, Microsatellite Stable (MSS) Colon Cancer
Interventions
Copanlisib, Nivolumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 29, 2026, 1:02 AM EDT
Completed Phase 3 Interventional

Insulin Glargine Vs Standard Insulin Therapy

NCT00222521
View directory record Official record
Conditions
Cystic Fibrosis Related Diabetes
Interventions
Glargine insulin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 22, 2005 · Synced Oct 29, 2026, 1:02 AM EDT
Recruiting No phase listed Observational

Lynch Syndrome Integrative Epidemiology and Genetics

NCT06582914
View directory record Official record
Conditions
Lynch Syndrome
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2054
U.S. locations
2
States / cities
Aurora, Colorado • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 29, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis

NCT03119649
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
GLPG2222 50 mg, GLPG2222 100 mg, Placebo, GLPG2222 200 mg, GLPG2222 400 mg
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years to 99 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
7
States / cities
Chatom, Alabama • Little Rock, Arkansas • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 29, 2026, 1:02 AM EDT
Recruiting Phase 4 Interventional

Ensuring Access to Optimal Therapy in CF: The ENACT Study

NCT07148739
View directory record Official record
Conditions
Cystic Fibrosis (CF)
Interventions
Elexacaftor / Ivacaftor / Tezacaftor, therapeutic drug monitoring
Drug · Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
3 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 29, 2026, 1:02 AM EDT
Active, not recruiting No phase listed Observational

Feasibility and Acceptance of SonoHeal for Airway Clearance and Preliminary Comparison With the Standard of Care

NCT07568119
View directory record Official record
Conditions
Cystic Fibrosis (CF), Non Cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Airway clearance therapy through acoustic oscillations
Device
Lead sponsor
Cognita Labs LLC
Industry
Eligibility
11 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 29, 2026, 1:02 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

NCT02347657
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-661 Plus Ivacaftor Combination, Ivacaftor, VX-661 Plus Ivacaftor Combination Placebo, Ivacaftor placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
27
States / cities
Little Rock, Arkansas • Long Beach, California • Denver, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 29, 2026, 1:02 AM EDT
Recruiting No phase listed Observational

Men at High Genetic Risk for Prostate Cancer

NCT03805919
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
30 Years to 75 Years · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2039
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 29, 2026, 1:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Interactive Mobile Health Information to Enhance Patient Care at a Cystic Fibrosis Center

NCT03052231
View directory record Official record
Conditions
Medication Adherence, Cystic Fibrosis
Interventions
caremessage
Device
Lead sponsor
Landon Pediatric Foundation
Other
Eligibility
4 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 29, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

NCT02709109
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-371 + HS, Hypertonic saline, Placebo, Orkambi, VX-371
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
12 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
30
States / cities
Little Rock, Arkansas • Oakland, California • Gainesville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 29, 2026, 1:02 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Comprehensive HHT Outcomes Registry of the United States (CHORUS)

NCT06259292
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformations, Telangiectasia, Epistaxis, GastroIntestinal Bleeding, Cerebral Arteriovenous Malformations, Vascular Malformation
Interventions
Not listed
Lead sponsor
Cure HHT
Other
Eligibility
Not listed
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2033
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 29, 2026, 1:02 AM EDT
Completed Phase 1 Interventional Results available

Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis

NCT01223183
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
hypertonic saline (7%), isotonic saline
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 29, 2026, 1:02 AM EDT
Recruiting Not applicable Interventional

Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials

NCT04580368
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
CFTR Modulators
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 29, 2026, 1:02 AM EDT
Completed Phase 3 Interventional Results available

Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation

NCT01707290
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
33
States / cities
Birmingham, Alabama • Palo Alto, California • Denver, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 29, 2026, 1:02 AM EDT
Completed No phase listed Observational

Tissue Bank for Pulmonary Diseases

NCT00546962
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 29, 2026, 1:02 AM EDT
Completed Phase 2 Interventional

Efficacy of Amiloride and Hypertonic Saline in Cystic Fibrosis

NCT00274391
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
7% NaCl, Amiloride HCl
Drug
Lead sponsor
University of North Carolina
Other
Eligibility
14 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 10, 2006 · Synced Oct 29, 2026, 1:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

OTIS Humira Pregnancy Registry

NCT01086059
View directory record Official record
Conditions
Crohn's Disease, Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
Female only
Enrollment
944 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 29, 2026, 1:02 AM EDT